TABLE 4.
Most common a grade ≥ 3 TEAEs in Chinese patients with relapsed/refractory B‐cell malignancies receiving zanubrutinib
| Preferred term, n (%) | 160 mg BID, (n = 34) | 320 mg QD, (n = 10) | Total, (N = 44) |
|---|---|---|---|
| Patients with ≥1 grade 3 or higher TEAE | 18 (52.9) | 6 (60.0) | 24 (54.5) |
| Neutrophil count decreased | 6 (17.6) | 5 (50.0) | 11 (25.0) |
| Anaemia | 4 (11.8) | 1 (10.0) | 5 (11.4) |
| Neutropenia | 4 (11.8) | 0 (0.0) | 4 (9.1) |
| Upper respiratory tract infection | 2 (5.9) | 2 (20.0) | 4 (9.1) |
| Pneumonia | 3 (8.8) | 0 (0.0) | 3 (6.8) |
| White blood cell count increased | 2 (5.9) | 1 (10.0) | 3 (6.8) |
| Platelet count decreased | 1 (2.9) | 1 (10.0) | 2 (4.5) |
| Thrombocytopenia | 1 (2.9) | 1 (10.0) | 2 (4.5) |
| White blood cell count decreased | 1 (2.9) | 1 (10.0) | 2 (4.5) |
Abbreviations: BID, twice daily; QD, once daily; TEAE, treatment‐emergent adverse event.
a
Occurring in ≥2 patients overall.